TMB-001 for the Treatment of Congenital Ichthyosis ASCEND
About the ASCEND Study
The purpose of this Phase 3 study is to investigate the efficacy and safety of TMB-001 (topical isotretinoin) for the treatment of congenital ichthyosis (CI). Furthermore, to investigate an optimal dosage for maintenance therapy with TMB-001.
What is TMB-001?
Many dermatologists are familiar with oral isotretinoin. By formulating isotretinoin into a proprietary topical formulation it may be possible to reduce systemic absorption, potentially allowing for chronic use over larger areas of the body. TMB-001 is being developed for the treatment of moderate to severe subtypes of CI. In 2018, the U.S. Food & Drug Administration (FDA) awarded an Orphan Products Grant to support the Phase 3 clinical trial evaluating TMB-001.